GlassScriptPhysician profile
John F Folan
NPI 1780801605
$2,591.75
in general payments reported to CMS, 2019-2025
34 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $132 · 2021: $50.09 · 2022: $340 · 2023: $691 · 2024: $747 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $400.17 | 2019-2025 | |
| Pfizer INC. | $250.57 | 2019-2025 | |
| Novo Nordisk INC | $233.14 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $224.42 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $132.93 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $129.65 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $119.80 | 2023-2024 | Rexulti, Nuedexta |
| Lilly USA, LLC | $110.53 | 2023-2025 | Jardiance, Emgality, Kisunla |
| Amarin Pharma, INC. | $100.40 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $87.39 | 2022 | |
| Merck Sharp & Dohme LLC | $86.25 | 2019-2024 | Dificid, Belsomra, Steglatro |
| Exact Sciences Corporation | $83.32 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $61.16 | 2022-2025 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $52.39 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $45.66 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.28 | 2019 | |
| Dynavax Technologies Corporation | $41.52 | 2024 | Heplisav-B |
| Lundbeck LLC | $41.13 | 2024 | Rexulti |
| Avvisto Therapeutics, LLC | $38.41 | 2024 | Cycloset |
| Bayer Healthcare Pharmaceuticals INC. | $35.36 | 2025 | |
| Procept Biorobotics Corporation | $34.74 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $28.18 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.59 | 2024 | |
| Jazz Pharmaceuticals INC. | $22.22 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.97 | 2022 | |
| Biogen, INC. | $20.82 | 2020 | |
| Mylan Specialty L.P. | $20.16 | 2024 | Yupelri |
| Arbor Pharmaceuticals, INC. | $19.84 | 2019 | |
| Dexcom, INC. | $18.03 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $14.65 | 2024 | (Ck7) Extended Holter |
| Sanofi Pasteur INC. | $13.88 | 2020 | |
| Ardelyx, INC. | $13.60 | 2024 | Ibsrela |
| Allergan, INC. | $13.33 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Folan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.